Smartlab Europe

Drug Research

Novel silica delivery system Nuvec (R) enters final pre-clinical development stage

N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company, has announced results fromthe company’s latest research study into its novel silica nanoparticle for cancer treatments and vaccines, Nuvec®. The work, which repeated and expanded on a previouspDNA OVA study,...

Sygnature Discovery moves US base to Kendall Square

Sygnature Discovery, the leading independent drug discovery and pre-clinical services company, has announced its US office has moved. The new office, at 245 First Street in Cambridge, MA, is near Kendall Square, the heart of the Cambridge–Boston biotech hub. It’s...

The rise and rise of Global Pharma Excipients Market

With the rise in the Global Pharma Industry, excipients too are bound to have their share of light. Of late, there has been an increasing demand for generic drugs which has, in turn, led to a rise of the...

Sygnature Discovery develops AR molecular visualisation prototype

The space occupied by a drug molecule in three dimensions, and how it fits into the target, is an important consideration when designing a new compound that might become a drug. Medicinal chemists commonly use 3D rendering software to...

Signant Health Brings Its eConsent Solution to China for Large Neuroscience Study in Collaboration with Shanghai Mental Health Center

Signant Health (formerly CRF Health and Bracket), a leading patient-centric technology company, has been selected to provide electronic informed consent for a significant neuroscience study by the prestigious Shanghai Mental Health Center (SMHC). This landmark investigator-led Schizophrenia trial, which...

Bora secures FDA approval for CDMO services

Bora, a contract development and manufacturing organization (CDMO) that specializes in modified release (MR) and solvent production, has reported a successful FDA general inspection for its facility in Zhunan, Taiwan. The publicly listed company recently hosted the site’s fifth successful...

Particle analysis: Growing demand with biologics

The development and introduction of new biological drug substances has been on the rise, and so have the regulatory requirements placed on these often life-saving products. At the same time, innovative analytical technologies have been developed that offer new...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »